All In Biotech

Drug Trial Radar · NCT01872702

Targeted Chemo-elimination (TCE) of Malaria

Targeted Chemo-elimination (TCE) to Eradicate Malaria in Areas of Suspected or Proven Artemisinin Resistance in Southeast Asia and South Asia

Last checked: Nov 20, 2026Latest source record: Aug 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 8,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,000

Actual

Start

Apr 2013

Primary completion

Jul 2017

Study completion Jul 2017

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Mahidol Oxford Tropical Medicine Research Unit; National Centre for Parasitology, Entomology and Malaria Control, Cambodia; FHI 360; Oxford University Clinical Research Unit, Vietnam; National Malaria Control Program, Vietnam; Myanmar Oxford Clinical Research Unit; National Malaria Control Program, Myanmar; Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit; Shoklo Malaria Research Unit
First posted
Jun 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 6 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The overall aim of this study is two fold: 1. to pilot targeted chemo-elimination of plasmodium falciparum malaria in known areas of artemisinin resistance in South East Asia. 2. to understand the micro-epidemiology of malaria in these areas; chiefly, the prevalence and importance to on-going transmission of sub-clinical p.f malaria infections.

Conditions

  • Plasmodium Falciparum Malaria

Interventions

  • malaria elimination using DP and low-dose primaquineDrug

    Treatment of all persons resident in the intervention villages including those who do not have malaria parasites as detected by rapid diagnostic test. This is to interrupt p.f malaria transmission by removing the reservoir of all potentially infectious people from the area.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. prevalence of falciparum malaria measured by qPCR (quantitative real time polymerase chain reaction), 12 months after the first administration of treatment with dihydroartemisinin-piperaquine and primaquine. (1017-13 and 23-15)Time frame: 12 months
  2. prevalence of falciparum malaria measured by qPCR (quantitative real time polymerase chain reaction), 12 months after the first administration of targeted malaria elimination (1015-13)Time frame: 12 months
  3. prevalence of falciparum malaria measured by qPCR (quantitative real time polymerase chain reaction), 4 months after the first administration of target malaria-elimination (23-15)Time frame: 4 months

Locations

5 sites in 5 countries. Site status is shown where the registry gives one.

  • Mahidol Oxford Clincal Research Unit, Myanmar

    Rangoon, Burma

  • Pailin

    Pailin, Cambodia

  • Savannakhet

    Savannakhet, Laos

  • Shoklo Malaria Research Unit

    Mae Sot, Changwat Tak, Thailand

  • Oxford University Clinical Research Unit - Vietnam

    Ho Chi Minh City, Vietnam

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.